Overview

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Status:
Not yet recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, non-randomized pilot study (Phase II). The aim is to obtain evidence of efficacy of niraparib and dostarlimab (TSR-042) in patients with relapsed ovarian cancer in two experimental cohorts and to generate data on PARPi (Poly(ADP-ribose)-Polymerase inhibitor) resistance and predictive biomarkers for IO (Immuno-Oncology) and PARPi.

Phase:

Phase 2

Details

Lead Sponsor:

AGO Research GmbH

Collaborator:

GlaxoSmithKline

Treatments:

Niraparib